TGFB1 and systemic sclerosis: Corrado et al. recently demonstrated that 25OHD supplementation was associated with a significant reduction of IL-17A and pro-fibrotic cytokines (FGF2, TGFβ, CTGF) both in patients with systemic sclerosis and in healthy subjects, with a dose-dependent effect [33].